Work

A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2585

Authors: Rebecca Sophie Kristeleit, Geoffrey Shapiro, Patricia LoRusso, Jeffrey R. Infante, Michael Flynn, Manish R. Patel, Sara M. Tolaney, John Frederick Hilton, Alan Hilary Calvert, Heidi Giordano, Jeffrey D. Isaacson, Jennifer Borrow, Andrew R. Allen, Sarah S. Jaw-Tsai, Howard A. Burris

Institutions: University College London, Dana-Farber Cancer Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Tennessee Oncology, Clovis Oncology (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597447452

Cites:

Cited by: 24

Related to: 10